-
-
-
-
-
-
-
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
-
-
-
-
-
-
-
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
-
-
-
-
-
-
-
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
-
-
-
-
-
-
-
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
-
-
-
-
-
-
-
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
-
-
-
-
-
-
-
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
-
-
-
-
-
-
-
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
-
1,157,576 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

